DENTSPLY SIRONA (NASDAQ:XRAY) Issues FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.400-1.500 for the period, compared to the consensus EPS estimate of 1.420. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Upgrades and Downgrades

XRAY has been the subject of several research analyst reports. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. Mizuho reduced their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Piper Sandler lifted their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Barclays lowered their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Thursday, June 4th. Finally, BMO Capital Markets started coverage on DENTSPLY SIRONA in a research report on Wednesday, July 8th. They set a “market perform” rating and a $12.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $13.46.

DENTSPLY SIRONA Stock Performance

XRAY stock traded down $0.61 during midday trading on Thursday, reaching $13.17. The company had a trading volume of 5,502,740 shares, compared to its average volume of 5,072,347. The firm has a market capitalization of $2.64 billion, a PE ratio of -4.18, a P/E/G ratio of 1.64 and a beta of 0.85. The stock has a 50 day moving average price of $11.74 and a 200 day moving average price of $11.89. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $14.86. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts anticipate that DENTSPLY SIRONA will post 1.42 earnings per share for the current year.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian P. Mckeon bought 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Brian T. Gladden purchased 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 35,160 shares of company stock valued at $351,179 in the last ninety days. Company insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares during the period. Lazard Asset Management LLC lifted its position in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after purchasing an additional 92,868 shares during the period. State Street Corp boosted its stake in DENTSPLY SIRONA by 5.5% during the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock valued at $113,868,000 after purchasing an additional 369,876 shares in the last quarter. Armistice Capital LLC increased its position in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after purchasing an additional 5,234,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after buying an additional 4,003,606 shares in the last quarter. Institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.